These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 5156174)

  • 21. [L-dopa and Parkinson's disease].
    Barbeau A
    Union Med Can; 1970 Dec; 99(12):2195-7. PubMed ID: 5488646
    [No Abstract]   [Full Text] [Related]  

  • 22. Levodopa in treating Parkinsonism.
    O'Doherty DS
    Am Fam Physician; 1971 Nov; 4(5):95-9. PubMed ID: 5117507
    [No Abstract]   [Full Text] [Related]  

  • 23. Quantitative analysis of the effects of L-dopa on gait in 26 patients with Parkinsonism.
    Peterson CR; Calvert JC; Canzoneri J; Leavitt LA; McCutchen JJ; Schwartz L
    Am J Phys Med; 1972 Aug; 51(4):171-81. PubMed ID: 5052844
    [No Abstract]   [Full Text] [Related]  

  • 24. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 25. Levodopa and induced-pain response. A study of patients with Parkinsonian and pain syndromes.
    Battista AF; Wolff BB
    Arch Intern Med; 1973 Jul; 132(1):70-4. PubMed ID: 4716428
    [No Abstract]   [Full Text] [Related]  

  • 26. [Current treatment of Parkinson syndrome with L-dopa].
    Gerstendbrand F; Gründig E; Musiol A
    Pol Tyg Lek; 1972 May; 27(21):798-800. PubMed ID: 4555002
    [No Abstract]   [Full Text] [Related]  

  • 27. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E; Mårtensson A
    Scand J Rehabil Med; 1974; 6(2):89-93. PubMed ID: 4837060
    [No Abstract]   [Full Text] [Related]  

  • 28. [L-dopa treatment of parkinsonism].
    Szulc-Kuberska J; Niewodniczy A; Poźniak-Patewicz E; Wolczyk-Orzechowska M
    Neurol Neurochir Pol; 1973; 7(1):63-8. PubMed ID: 4511385
    [No Abstract]   [Full Text] [Related]  

  • 29. L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1971 Aug; 26(8):61-70. PubMed ID: 5096462
    [No Abstract]   [Full Text] [Related]  

  • 30. Levodopa in parkinson's disease--Australian collaborative trial.
    Selby G
    Med J Aust; 1973 Mar; 1(12):577-85. PubMed ID: 4700544
    [No Abstract]   [Full Text] [Related]  

  • 31. L-DOPA in Parkinson's disease. Results of a co-operative study in the Montreal area.
    Mars H; Libman I; Schwartz AM; Gillo-Joffroy L; Barbeau A
    Can Psychiatr Assoc J; 1972 Apr; 17(2):123-31. PubMed ID: 5036506
    [No Abstract]   [Full Text] [Related]  

  • 32. External work of walking and functional capacity in Parkinsonian patients treated with L-dopa.
    Gersten JW; Marshall C; Dillon T; Schneck SA; Orr W; Nelson C
    Arch Phys Med Rehabil; 1972 Dec; 53(12):547-53. PubMed ID: 4648427
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical experience with L-DOPA in the treatment of parkinsonism].
    Chiba T
    No To Shinkei; 1970 Dec; 22(12):1399-405. PubMed ID: 5536833
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of parkinsonism with L-dopa].
    Court J; Kase JC; Palacios E; Mena I
    Rev Med Chil; 1971 Jun; 99(6):399-401. PubMed ID: 5561157
    [No Abstract]   [Full Text] [Related]  

  • 35. [Therapeutic effects of L-dopa and trihexyphenidyl in Parkinson's disease--an examination by a double blind method].
    Hirayama K; Uono M; Nakanishi T; Kato N; Nagao Y
    Shinkei Kenkyu No Shimpo; 1971; 15(1):267-85. PubMed ID: 4937721
    [No Abstract]   [Full Text] [Related]  

  • 36. Parkinson's disease treated with L-dopa. Three-year follow-up report.
    Mones RJ
    N Y State J Med; 1972 Nov; 72(22):2749-50. PubMed ID: 4510706
    [No Abstract]   [Full Text] [Related]  

  • 37. [Study of L-dopa treatment and its principal side effects in aged subjects].
    Antonini F; Baroni A; Bucalossi A; Roveyaz L
    Gerontol Clin (Basel); 1972; 14(5):297-309. PubMed ID: 4144357
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy of and possible differences in tolerance to L-dopa tablets with different rates of release of the active substance.
    Völler GW; Muschard F
    Acta Neurol Scand; 1974; 50(3):391-3. PubMed ID: 4525037
    [No Abstract]   [Full Text] [Related]  

  • 39. [Case reports of some mental disorders in parkinsonian patients treated with L-dopa].
    Almici GM; Sbarbaro V
    Minerva Med; 1974 Feb; 65(8):398-401. PubMed ID: 4820722
    [No Abstract]   [Full Text] [Related]  

  • 40. L-dopa. II.
    Br Med J; 1970 Nov; 4(5734):541-2. PubMed ID: 4099003
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.